InvestorsHub on MSN
Novavax shares gain after Matrix-M adjuvant licensing deal with Pfizer
Novavax (NASDAQ:NVAX) shares climbed about 5% on Tuesday after the biotech group disclosed a non-exclusive licensing ...
Novavax’s CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a recent ...
The agreement allows Pfizer to utilize Novavax’s Matrix-M adjuvant in up to two disease areas with its products. Under the terms of the deal, Novavax will receive an upfront payment of $30 million and ...
DG Matrix announces the first field deployment of its breakthrough Power Router technology to accelerate global electrification and alleviate grid constraints. In a bold move to leapfrog the entire ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback